Protective immunization against murine cytomegalovirus infection using adenoviruses and poxviruses expressing hepatitis B virus chimeras

International Microbiology

Volumn 10, Issue 4, 2007, Pages 261-269

  De Andrade, Bruna P ^a   Gazzinelli, Ricardo T ^a,c   Del Val, Margarita ^b   Bruna Romero, Oscar ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cellular immunity; Cytomegalovirus; Prime boost immunization; Recombinant adenovirus; Vaccines

Indexed keywords

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS; HEPATITIS B VIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MURID HERPESVIRUS 1; MUS; VACCINIA VIRUS;

EID: 38949200233     PISSN: 11396709     EISSN: 16181905     Source Type: Journal    
DOI: 10.2436/20.1501.01.35     Document Type: Article

References (34)

1. Brown K, Gao W, Alber S, et al. (2003) Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 171:6875-6882
2. Bruna-Romero O, Lasarte JJ, Wilkinson G, et al. (1997) Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25:470-477
3. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS (2001) Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 98:11491-11496
4. Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT (2004) Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 22:3575-3584
5. Caetano BC, Bruna-Romero O, Fux B, Mendes EA, Penido ML, Gazzinelli RT (2006) Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther 17:415-426
6. Carvalho LH, Hafalla JC, Zavala F (2001) ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses. J Immunol Methods 252:207-218
7. Del Val M, Volkmer H, Rothbard JB, et al. (1988) Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol 62:3965-3972
8. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH (1991) Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66:1145-1153
9. Del Val M, Schlicht HJ, Volkmer H, Messerle M, Reddehase MJ, Koszinowski UH (1991) Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65:3641-3646
10. Esparza J (2005) The Global HIV Vaccine Enterprise. Int Microbiol 8:93-101
11. Gil-Torregrosa BC, Raul Castano A, Del Val M (1998) Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J Exp Med 188:1105-1116
12. Gonzalez Armas JC, Morello CS, Cranmer LD, Spector DH (1996) DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70:7921-7928
13. Holtappels R, Pahl-Seibert MF, Thomas D, Reddehase MJ (2000) Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62Llo memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol 74:11495-11503
14. Hutchings CL, Gilbert SC, Hill AV, Moore AC (2005) Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175:599-606
15. Jacobs SC, Stephenson JR, Wilkinson GW (1992) High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol 66:2086-2095
16. Levrero M, Barban V, Manteca S, et al. (1991) Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. Gene 101:195-202
17. + T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 90:5214-5218
18. MacDonald MR, Li XY, Stenberg RM, Campbell AE, Virgin HW (1998) Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J Virol 72:442-451
19. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, Bruna-Romero O (2006) Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17:898-908
20. Mackett M, Smith GL, Moss B (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79:7415-7419
21. McDermott MR, Graham FL, Hanke T, Johnson DC (1989) Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169:244-247
22. McGrory WJ, Bautista DS, Graham FL (1988) A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163:614-617
23. Molinier-Frenkel V, Lengagne R, Gaden F, et al. (2002) Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76:127-135
24. Montoya M, Del Val M (1999) Intracellular rate-limiting steps in MHC class I antigen processing. J Immunol 163:1914-1922
25. Morello CS, Ye M, Spector DH (2002) Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J Virol 76:4822-4835
26. Oliveira GA, Wetzel K, Calvo-Calle JM, et al. (2005) Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73:3587-3597
27. Pahl-Seibert MF, Juelch M, Podlech J, et al. (2005) Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 79:5400-5413
28. Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79:4927-4931
29. Panicali D, Davis SW, Weinberg RL, Paoletti E (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA 80:5364-5368
30. Prevec L, Campbell JB, Christie BS, Belbeck L, Graham FL (1990) A recombinant human adenovirus vaccine against rabies. J Infect Dis 161:27-30
31. Ramshaw IA, Ramsay AJ (2000) The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21:163-165
32. Rocha CD, Caetano BC, Machado AV, Bruña-Romero O (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7:83-94
33. Simon CO, Holtappels R, Tervo HM, et al. (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436-10456
34. Thummel C, Tjian R, Grodzicker T (1981) Expression of SV40 T antigen under control of adenovirus promoters. Cell 23:825-836